Approximately 246 million adults have diabetes worldwide. This number is expected to grow to 380 million by the year 2025. Physical activity reduces the incidence of diabetes in patients with impaired glucose tolerance but is difficult to maintain. Anti-diabetic agents decrease progression to diabetes but can have adverse cardiovascular effects. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers decrease incident diabetes in clinical trials in patients with cardiovascular disease. An effect of ACE inhibition on incident diabetes was not replicated in patients with impaired fasting glucose in the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication trial. In the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research study, valsartan did not improve cardiovascular mortality even though incident diabetes was reduced. Our recent data suggest that the effect of interruption of the renin-angiotensin-aldosterone system may depend on the extent to which aldosterone is decreased, as aldosterone modulates glucose-stimulated insulin secretion in vivo and in vitro. At the same time, short-term studies funded by this grant over the last four years support the hypothesis that pharmacologic measures to increase cyclic guanosine monophosphate (cGMP) improve glucose homeostasis. We have found that acutely increasing the formation of endogenous nitric oxide increases muscle glucose uptake in humans;however, nitric oxide also decreases vascular tissue plasminogen activator release through a cGMP-independent mechanism. In contrast, three-week treatment with the phosphodiesterase 5 (PDE5) inhibitor tadalafil improves beta cell function in subjects with the metabolic syndrome without altering fibrinolytic balance. PDE5 inhibitors have been approved for the long-term treatment of pulmonary hypertension, improve many biomarkers of endothelial function and appear to be safe in patients at risk for cardiovascular events. Therefore, in this proposal, we test the hypothesis that long-term PDE5 inhibition improves glucose homeostasis in individuals with impaired glucose tolerance by improving beta cell function. Specifically, we will test the hypothesis that 3-month treatment with sildenafil improves glucose-stimulated insulin secretion, as measured using hyperglycemic clamp (Aim 1). Based on prior studies in rodent models, we will also consider the alternative hypothesis that 3-month PDE5 inhibition improves insulin sensitivity, as measured using euglycemic-hyperinsulinemic clamp (Aim 2). We hypothesize that long-term administration of the PDE5 inhibitor sildenafil will improve measures of glucose homeostasis in patients with impaired glucose tolerance, while improving biomarkers of fibrinolysis. With a number of new pharmacological strategies to increase cGMP emerging, these studies could have a major impact on the incidence of diabetes and its associated cardiovascular morbidity.

Public Health Relevance

The number of adults with diabetes in the world is expected to grow to 380 million by the year 2025. Identifying drugs that prevent the development of diabetes in high-risk individuals could have a major health impact. In this proposal, we follow up on data from animal studies and a short-term study in humans to test the hypothesis that long-term administration of the commonly prescribed drug sildenafil (Viagra, Revatio) improves insulin secretion and/or increases insulin sensitivity in high-risk individuals.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL060906-15
Application #
8437170
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Reid, Diane M
Project Start
1998-08-18
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
15
Fiscal Year
2013
Total Cost
$408,110
Indirect Cost
$146,501
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Luther, James M; Byrne, Loretta M; Yu, Chang et al. (2014) Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans. J Clin Endocrinol Metab 99:E1895-902
Marney, Annis M; Brown, Nancy J; Tamboli, Robyn et al. (2014) Changes in B-type natriuretic peptide and BMI following Roux-en-Y gastric bypass surgery. Diabetes Care 37:e70-1
Devin, Jessica K; Pretorius, Mias; Nian, Hui et al. (2014) Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension 63:951-7
Ramirez, Claudia E; Shuey, Megan M; Milne, Ginger L et al. (2014) Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. Prostaglandins Other Lipid Mediat 113-115:38-44
Devin, Jessica K; Pretorius, Mias; Nian, Hui et al. (2014) Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm. J Am Heart Assoc 3:
Brown, Nancy J (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9:459-69
Luo, P; Dematteo, A; Wang, Z et al. (2013) Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia 56:901-10
Gilbert, Kimberly; Nian, Hui; Yu, Chang et al. (2013) Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens 31:820-9
White, C C; Feng, Q; Cupples, L A et al. (2013) CYP4A11 variant is associated with high-density lipoprotein cholesterol in women. Pharmacogenomics J 13:44-51
Brown, Nancy J (2012) Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. J Am Soc Hypertens 6:163-8

Showing the most recent 10 out of 73 publications